LANGLEY, R.; THACI, D.; BLAUVELT, A. .; TSAI, T.-F.; MILLER, M. .; YU, J.; SHEN, Y.-K. .; YOU, Y.; YANG, Y.-W.; PAPP, K. .; PUIG, L.; FOLEY, P. Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated with Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 2, p. s1, 2022. DOI: 10.25251/skin.6.supp.1. Disponível em: Acesso em: 11 aug. 2022.